Compare Teucrium Wheat Fund (WEAT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Wheat Fund vs State Street SPDR S&P Biotech ETF — how do they compare? Teucrium Wheat Fund trades at $24.49, while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals.
| WEAT | XBI | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $26.00 | $164.28 |
52-Week Low | $19.88 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WEAT (Teucrium Wheat Fund) trades at $24.36, up 1.46% over the past day, with a bullish technical signal driven by moving averages. Recent performance includes a 9.9% gain over the past month and a 25% year-to-date increase as of Zacks Investment Research on July 21, 2026. The USDA reduced its 2026 U.S. wheat production outlook to 1.56 billion bushels on May 12, 2026, influencing commodity-driven volatility.
The outlook remains positive due to strong momentum and inflation hedging appeal, but risks include agricultural supply shocks and macroeconomic pressures. Investors should weigh the fund's exposure to wheat price swings against potential for continued commodity strength amid ongoing inflation concerns highlighted by ETF Trends as of June 2026.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
